Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9859075 | 0.88 | CYP3A4 (0.38) | CYP3A4TRPA1SMN1; SMN2MAPK1TDP1 | |
| SCHEMBL9859232 | 0.80 | CYP3A4 (0.49) | CYP3A4TRPA1MAPK1TDP1PDE2A | |
| SCHEMBL10918491 | 0.78 | TDP1 (0.41) | CYP3A4TRPA1MAPK1TDP1SLC1A5 | |
| SCHEMBL17130393 | 0.78 | EPHX2 (0.46) | CYP3A4TRPA1MAPK1TDP1PDE2A | |
| SCHEMBL3977319 | 0.77 | MAPK1 (0.40) | CYP3A4TRPA1MAPK1TDP1PDE2A | |
| SCHEMBL1555311 | 0.77 | MAPK1 (0.56) | CYP3A4TRPA1MAPK1TDP1SLC1A5 | |
| SCHEMBL2646886 | 0.75 | L3MBTL1 (0.47) | SMN1; SMN2GSTO1PDE2ASLC22A12EGLN1 | |
| SCHEMBL29873844 | 0.75 | SLC22A12 (0.38) | CYP3A4TRPA1MAPK1TDP1SLC22A12 | |
| SCHEMBL21239459 | 0.75 | SLC22A12 (0.38) | CYP3A4TRPA1MAPK1TDP1SLC22A12 | |
| SCHEMBL1555247 | 0.74 | MAPK1 (0.56) | CYP3A4TRPA1MAPK1TDP1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282811-A1 | Diazabicyclic histamine-3 receptor antagonists | PFIZER INC | 2005-12-22 | — | — | US | claimed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20050282811-A1 | Diazabicyclic histamine-3 receptor antagonists | PFIZER INC | 2005-12-22 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TRPA1 3353/4885SMN1; SMN2 3528/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TRPA1 3353/4885SMN1; SMN2 3528/4885 |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 2800/4885TRPA1 3802/4885SMN1; SMN2 3973/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TRPA1 3353/4885SMN1; SMN2 3528/4885 |
| US-20050282811-A1 | Diazabicyclic histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | CYP3A4 1729/4885TRPA1 486/4885SMN1; SMN2 1409/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 2800/4885TRPA1 3802/4885SMN1; SMN2 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.